Digital Therapeutics Market: AI-Driven Care Models, Remote Monitoring & Industry Growth Outlook

According to IMARC Group's latest research publication, the global digital therapeutics market size reached USD 7.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 28.7 Billion by 2033, exhibiting a growth rate (CAGR) of 16.8% during 2025-2033.

How Ai Is Reshaping the Future of Digital Therapeutics Market

• Precision Diagnosis and Personalization: AI-driven algorithms analyze patient health data to deliver highly personalized treatment plans, adapting interventions in real-time based on monitored physiological parameters and behavioral patterns for improved therapeutic outcomes.
• Predictive Analytics and Early Intervention: Machine learning models process large datasets to identify disease risk patterns early, enabling proactive interventions that prevent condition progression and reduce long-term healthcare costs through timely digital therapeutic deployment.

• Enhanced Patient Engagement and Adherence: Natural language processing powers conversational AI chatbots that provide 24/7 support, motivational prompts, and adaptive content delivery, significantly boosting patient engagement and treatment adherence rates across chronic disease management programs.

Access Updated Market Insights in a Sample Report

Digital Therapeutics Industry Overview

The FDA's Digital Health Center of Excellence is transforming the regulatory landscape for digital therapeutics, with over 1,250 AI-enabled medical devices now authorized for marketing in the United States. In December 2024, the FDA released final guidance on Predetermined Change Control Plans for AI-enabled devices, allowing manufacturers to implement continuous improvements without repeated regulatory reviews.

Digital Therapeutics Market Trends & Drivers

Rising chronic disease burden is the primary catalyst driving digital therapeutics adoption worldwide. Global diabetes cases continue climbing, with digital platforms offering real-time blood glucose monitoring, personalized insulin dosing recommendations, and dietary guidance that stabilizes patient conditions.

Regulatory approvals and reimbursement frameworks are accelerating market expansion across major healthcare systems. The FDA's Digital Health Advisory Committee, established in November 2024, provides expert guidance on fast-moving digital health and AI issues, building industry confidence through clear regulatory pathways.

Technological innovation and strategic partnerships are reshaping how digital therapeutics reach patients and demonstrate clinical value. Biofourmis partnered with healthcare systems in 2024 to integrate AI-powered analytics and continuous monitoring platforms into standard care, demonstrating significantly lower hospitalization rates for heart failure patients.

Digital Therapeutics Market Report Segmentation

By Application:

• Diabetes
• Obesity
• CVD
• CNS Disease
• Respiratory Diseases
• Smoking Cessation
• Others

Diabetes represents the largest class, as digital platforms enable continuous blood glucose monitoring, personalized insulin management, and dietary recommendations that improve patient outcomes while reducing healthcare costs.

By End Use:

• Patients
• Providers
• Payers
• Employers
• Others

Patients have the largest market share owing to widespread smartphone adoption, patient-centric healthcare models, and growing preference for accessible, personalized digital treatment solutions for chronic condition management.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America exhibits clear dominance in the digital therapeutics market due to advanced healthcare infrastructure, significant digital health investments, and favorable regulatory frameworks supporting innovation.

Recent News and Developments in Digital Therapeutics Market

• March 2025: Click Therapeutics raised USD 145 million in Series C funding, backed by Medidata and Dassault Systemes, to scale its clinical pipeline including CT-132 for migraine reduction and software-enhanced drug therapies under its Click SE platform.
• March 2025: ATA Action acquired the Digital Therapeutics Alliance (DTA), establishing a robust platform for advocacy and policy aimed at promoting cutting-edge technologies revolutionizing patient care and increasing digital therapeutics availability.
• February 2025: Headspace merged with Ginger, forming a combined USD 3 billion digital mental health company offering comprehensive 24/7 on-demand behavioral health coaching, therapy, psychiatry, and self-guided mobile app support.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.